Stocklytics Platform
Asset logo for symbol NKTX
Nkarta
NKTX49
$2.44arrow_drop_down0.20%-$0.00
Penny Stock
Asset logo for symbol NKTX
NKTX49

$2.44

arrow_drop_down0.20%
Key Stats
Open$2.51
Prev. Close$2.49
EPS-1.83
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$177.83M
PE Ratio-
LOWHIGH
Day Range2.39
2.58
52 Week Range1.32
16.24
Ratios
Revenue-
EBITDA Margin %-
EPS-1.83
Fundamentals
Gross Profit-
P/S Ratio-
Payout Ratio-
Industry average yield2.72%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

NKTX-
US Healthcare Sector-
US Market-
warning

NKTX / Market

NKTX lose to the US Market which returned 0.00% over the last twenty four hours.
warning

NKTX / Healthcare Sector

NKTX lose to the US Healthcare sector which returned 2.45% over the last twenty four hours.

Nkarta (NKTX) Statistics

Nkarta Inc (NKTX) is a biotech company that specializes in developing and commercializing cell therapies for various diseases. The company is focused on using natural killer (NK) cells to treat cancer and other disorders. NK cells are a type of immune cell that can recognize and kill abnormal cells, including cancerous cells. Nkarta Inc believes that NK cell therapy has the potential to be a transformative treatment for cancer patients.
When analyzing NKTX stock, it's important to consider the valuation metrics. These metrics can provide insights into the company's market value and potential growth prospects. One such metric is the enterprise to EBITDA ratio, which measures the company's enterprise value relative to its earnings before interest, tax, depreciation, and amortization. A lower ratio may indicate that the stock is undervalued, while a higher ratio could suggest overvaluation.
add Nkarta  to watchlist

Keep an eye on Nkarta

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Nkarta (NKTX) stock's performance compared to its sector and the market over the past year?

Over the past year, Nkarta (NKTX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 28.29%, Nkarta has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 59.85%, it has fallen short of the market average. This comparison highlights Nkarta 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Nkarta (NKTX) stock?

The PE ratio for Nkarta (NKTX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Nkarta (NKTX) stock?

The Earnings Per Share (EPS) for Nkarta (NKTX), calculated on a diluted basis, is -$1.83. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Nkarta (NKTX) stock?

The operating margin for Nkarta (NKTX) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Nkarta (NKTX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Nkarta (NKTX) is -$118.14M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Nkarta (NKTX) have?

Nkarta (NKTX) has a total debt of $85.45M. The net debt, which accounts for cash and cash equivalents against the total debt, is $28.49M.

Take Your Investments to a Whole New Level